{
    "clinical_study": {
        "@rank": "151385", 
        "arm_group": {
            "arm_group_label": "ALT-803", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of\n      ALT-803 in patients with surgically incurable advanced melanoma."
        }, 
        "brief_title": "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "This trial will investigate the safety and immunogenicity, immunomodulatory properties, and\n      clinical benefits of treatment with weekly doses of ALT-803 administered intravenously in\n      patients with advanced melanoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "ENTRY CRITERIA:\n\n        DISEASE CHARACTERISTICS:\n\n          -  Confirmed metastatic or unresectable melanoma for which standard curative or\n             palliative measures do not exist or are no longer effective.\n\n          -  Primary site may be cutaneous or unknown, but mucosal and ocular primaries are\n             excluded.\n\n          -  No patients with known brain metastases.\n\n        PRIOR/CONCURRENT THERAPY:\n\n          -  At least one prior therapy using an agent with the potential for prolonged remission.\n\n          -  Patients with BRAF v600 mutation should be excluded or may be included after\n             experiencing progression following treatment with BRAF inhibitor regimen or if they\n             consent to forgo FDA-approved therapies that increase median survival.\n\n          -  At least 4 weeks from last dose of prior chemotherapy or non-antibody immunomodulator\n             therapy with full recovery of acute toxicities.\n\n          -  At least 2 weeks from last dose for patients coming off of BRAF inhibitor or other\n             molecularly targeted therapy with full recovery of toxicities.\n\n          -  At least 2 weeks from completion of prior radiation therapy with full recovery from\n             toxicities.\n\n          -  At least 4 weeks from last dose of prior investigational therapy with full recovery\n             from toxicities.\n\n          -  Not receiving any current anticancer therapy\n\n          -  At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies.\n\n          -  No patients who have had chemotherapy or radiotherapy within 4 weeks, 6 weeks for\n             nitrosoureas or mitomycin C.\n\n          -  No patients who are receiving any other investigational agents.\n\n          -  No chronic systemic or regular inhaled corticosteroid use within 7 days of treatment\n             start.\n\n          -  No immunosuppressive therapy within 30 days prior to treatment start.\n\n        PATIENT CHARACTERISTICS\n\n          -  Age >18 years\n\n          -  Both men and women of all races and ethnic groups are eligible.\n\n        Performance Status\n\n          -  ECOG performance status \u22641\n\n          -  Life expectancy of greater than 6 months.\n\n        Bone Marrow Function\n\n          -  leukocytes \u22653,000/mcL\n\n          -  absolute lymphocyte count \u2265500/mcL\n\n          -  absolute neutrophil count \u22651,000/mcL (without hematopoietic growth factors)\n\n          -  platelets  \u2265100,000/mcL (without transfusion)\n\n          -  hemoglobin \u2265 10 gm/dL (may be transfused but must be stable without clinical evidence\n             of ongoing blood loss or hemolysis)\n\n        Hepatic Function\n\n          -  total bilirubin within normal institutional limits\n\n          -  AST(SGOT)/ALT(SGPT) \u22642.5 \u00d7 institutional upper limit of normal\n\n        Kidney Function\n\n          -  Creatinine within normal institutional limits OR\n\n          -  Creatinine clearance \u226560 mL/min/1.73 m2 for patients with creatinine levels above\n             institutional normal.\n\n        Pulmonary Function\n\n        \u2022 Pulmonary function FEV1 \u2265 2 liters or \u2265 75% of predicted for height and age (required\n        for patients with history of pulmonary disease, prolonged smoking history or respiratory\n        dysfunction).\n\n        Cardiac Function\n\n          -  No symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia. Patients who have underlying risk factors for cardiac disease should be\n             excluded or undergo clearance stress-based cardiac function testing. The\n             pre-treatment QTc must be <500 msec.\n\n          -  No class II or greater congestive heart failure as described in the New York Heart\n             Association Functional Classification criteria or serious arrhythmias likely to\n             increase the risk of cardiac complications of cytokine therapy.\n\n        Other\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n          -  No uncontrolled inter-current illness or psychiatric illness/social situations that\n             would limit compliance with study requirements.\n\n          -  No pregnant women.\n\n          -  No HIV-positive patients.\n\n          -  No positive hepatitis C serology or active hepatitis B infection.\n\n          -  No active bacterial or fungal infection.\n\n          -  No inability to home monitor blood pressure.\n\n          -  Patients with thyroid disease should be excluded unless euthyroid on suppressive or\n             replacement therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946789", 
            "org_study_id": "CITN06-ALT-803", 
            "secondary_id": "U01CA154967"
        }, 
        "intervention": {
            "arm_group_label": "ALT-803", 
            "description": "Intravenous infusion; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles", 
            "intervention_name": "ALT-803", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cancer", 
            "IL-15", 
            "melanoma", 
            "metastatic", 
            "unresectable"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "NIH Patient Recruitment", 
                    "phone": "800-411-1222"
                }, 
                "contact_backup": {
                    "email": "tawald@mail.nih.gov", 
                    "last_name": "Thomas A Waldmann, MD", 
                    "phone": "301-496-6656"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "National Institutes of Health"
                }, 
                "investigator": {
                    "last_name": "Thomas A Waldmann, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "eryn.m.bagley@hitchcocok.org", 
                    "last_name": "Eryn M Bagley", 
                    "phone": "603-650-4035"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth Hitchcock Medical Center"
                }, 
                "investigator": {
                    "last_name": "Marc Ernstoff, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kcyim@seattlecca.org", 
                    "last_name": "Kelly Yim", 
                    "phone": "206-288-7565"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "University of Washington, Seattle Cancer Care Alliance"
                }, 
                "investigator": {
                    "last_name": "Kim Margolin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Melanoma", 
        "overall_contact": {
            "email": "hingwong@altorbioscience.com", 
            "last_name": "Hing Wong, Ph.D.", 
            "phone": "954-443-8600", 
            "phone_ext": "801"
        }, 
        "overall_official": {
            "affiliation": "University of Washington, Seattle Cancer Care Alliance", 
            "last_name": "Kim Margolin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety and effectiveness of ALT-803 on the peripheral blood white blood cell (WBC) and absolute lymphocyte (ALC) counts. Defined by the increase in the total number of peripheral lymphocytes during the first cycle. The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which \u22652 of 6 patients experience a DLT. The efficacy endpoint is the OBD, defined as that which produces an ALC \u226525,000/\u00b5L and/or a total WBC \u226535,000/\u00b5L among 2/3 of patients. For safety, we have also defined an \"exceeding OBD\" as the occurrence of ALC \u226535,000/\u00b5L and/or WBC \u226550,000/\u00b5L.", 
            "measure": "Safety profile and effectiveness of escalating doses of ALT-803", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946789"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "On the number and phenotype of peripheral blood mononuclear cells (PBMCs)by multiparameter blood flow, the level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-\u03b3) ELISPOT, immunogenicity and pharmacokinetics of ALT-803 assessed by ELISA and overall objective response rate (ORR) and response duration assessed by evidence of antitumor activity as defined by objective responses and the pharmacokinetic and pharmacodynamic profiles of ALT-803", 
            "measure": "To evaluate the effect of escalating doses of ALT-803", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "Altor Bioscience Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Altor Bioscience Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}